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Background: Cell therapy of liver diseases with human biliary tree stem cells (hBTSCs) is biased by low engraftment
efficiency. Coating the hBTSCs with hyaluronans (HAs), the primary constituents of all stem cell niches, could facilitate
cell survival, proliferation, and, specifically, liver engraftment given that HAs are cleared selectively by the liver.
Methods: We developed a fast and easy method to coat hBTSCs with HA and assessed the effects of HA-coating on
cell properties in vitro and in vivo.
Results: The HA coating markedly improved the viability, colony formation, and population doubling of hBTSCs
in primary cultures, and resulted in a higher expression of integrins that mediate cell attachment to matrix
components. When HA-coated hBTSCs were transplanted via the spleen into the liver of immunocompromised
mice, the engraftment efficiency increased to 11% with respect to 3% of uncoated cells. Notably, HA-coated
hBTSC transplantation in mice resulted in a 10-fold increase of human albumin gene expression in the liver and
in a 2-fold increase of human albumin serum levels with respect to uncoated cells. Studies in distant organs
showed minimal ectopic cell distribution without differences between HA-coated and uncoated hBTSCs and,
specifically, cell seeding in the kidney was excluded.
Conclusions: A ready and economical procedure of HA cell coating greatly enhanced the liver engraftment of
transplanted hBTSCs and improved their differentiation toward mature hepatocytes. HA coating could improve
outcomes of stem cell therapies of liver diseases and could be immediately translated into the clinic given that
GMP-grade HAs are already available for clinical use.
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Liver transplantation is the only therapeutic option for
many congenital and acquired liver diseases [1–3]. How-
ever, the requirements of this procedure and the paucity of
organs available for transplantation limit this option to a
minority of patients [1–3]. Cell therapy is a promising* Correspondence: eugenio.gaudio@uniroma1.it;
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sources have been tested, including hepatic stem cells
(HpSCs), biliary tree stem cells (BTSCs), mesenchymal
stem cells, adipose-derived stem cells, umbilical cord cells,
amniotic fluid-derived epithelial cells, embryonic stem cells
(ESCs), and induced pluripotent stem (iPS) cells [1, 2].
Recently, we successfully transplanted patients with
advanced cirrhosis by infusing human biliary tree stem
cells (hBTSCs) into the hepatic artery [1]. However, the
homing and the liver engraftment of administered cells
remain a key issue. Transplantation of such stem cell
populations via the portal vein results in less than 5%
engraftment [3, 5, 6]. Direct injection into the liver par-
enchyma results in ~10–20% engraftment [7]. Thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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cells into the liver via a vascular route was reported by
Khan et al. [8] who administered the cells via the hepatic
artery. These findings were corroborated by others [9].
In addition, transplantation by any vascular route, either
portal vein, hepatic artery, or spleen, resulted in signifi-
cant ectopic cell distribution to the vascular beds of all
tissues assayed. Moreover, the cells survived for months,
increasing the risk of ectopic liver formation with un-
known clinical consequences [7]. There is therefore a
need for methods to increase localization of the trans-
planted cells to the target tissue.
Coinjection of human HpSCs with hyaluronans (HAs)
triggered to form HA hydrogels into the livers of im-
munocompromised mice resulted in essentially 100% en-
graftment, an absence of ectopic cell distribution, and an
extent of humanization of host livers at 2 weeks compar-
able with that at 3–5 months if transplanted without HA
[7]. The use of natural and synthetic scaffolds has been
considered by many [3, 7, 9–12].
HAs are of especial interest for stem cell therapies.
They are polymers of the glucuronic acid–N-acetyl
glucosamine dimer, are anionic, are nonsulfated, and
are major constituents of all stem cell niches. HAs can
be prepared as liquids that can be converted into
hydrogels with remarkable chemical and mechanical
properties ideal for cell populations, having perfect
elasticity and enabling interstitial fluids complete ac-
cess throughout the gel [11]. In addition, diverse forms
of HA receptors, CD44 isoforms, are generic bio-
markers of all known stem cell populations [13]. HAs,
both in liquid and hydrogel forms, have been shown to
promote stem cell survival and proliferation, to
optimize spheroid/organoid formation of normal and
transformed stem cells, and to optimize cryopreserva-
bility of stem cells [7, 11, 14–17]. They have also dem-
onstrated promise in cell delivery [7, 18–21]. It is
noteworthy that HA is renowned for fostering
vascularization, and is readily modified by the cells as
needed for integration into the tissue and with enzymes
(e.g., hyaluronidases) and by hydrolysis native to the
liver [7, 11, 18–21].
As a novel strategy to improve the liver engraftment of
hBTSCs we are proposing to coat hBTSCs with HAs
and to use them for cell therapy of liver diseases. We
hypothesize that this strategy could be successful for the
liver given that HA is selectively and specifically cleared
by the liver [22, 23]. Moreover, HAs are largely used for
different clinical applications, facilitating their use also
in the setting of cell therapy [12]. The main objectives of
the present study were to evaluate the effect of HA coat-
ing: in vitro, on engraftment, proliferation, and differen-
tiation of hBTSCs in primary cultures; and in vivo, on
engraftment efficiency into the liver and differentiationtoward mature hepatocytes of hBTSCs transplanted, via
the spleen, into immune-compromised mice.Methods
Human tissue sourcing
The cell source consisted of freshly isolated human bil-
iary tree stem/progenitor cells (hBTSCs) obtained from
the human extrahepatic biliary tree, comprising the
common hepatic duct, bile duct, cystic duct, gallbladder,
and hepato-pancreatic ampulla. Biliary tissues were ob-
tained from organ donors because they were not used
for transplantation at the “Paride Stefanini” Department
of General Surgery and Organ Transplantation, Sapienza
University of Rome, Rome, Italy. Informed consent to
use tissues for research purposes was obtained from our
transplant program. All samples derived from adults be-
tween the ages of 19 and 73 years. Protocols received
the approval of our Institutional Review Board, and pro-
cessing was compliant with current Good Manufacturing
Practice (cGMP). The research protocol was reviewed
and approved by the Ethic Committee of Umberto I
University Hospital, Rome, Italy. Freshly isolated
hBTSCs have been characterized extensively in previous
reports [24–26]. In the present report, the in-vitro ex-
periments were performed by culturing primary freshly
isolated cells, which were not passaged. Each set of ex-
periments was performed on cells isolated from five dif-
ferent patients, in triplicate for each patient.Tissue processing
Tissue specimens were processed as described previously
[7, 24, 25, 27, 28]. In brief, tissues were digested in RPMI
1640 supplemented with 0.1% human serum albumin, 1
nM selenium, antibiotics, type I collagenase (300 colla-
gen digestion units/ml), 0.3 mg/ml deoxyribonuclease, at
37 °C with frequent agitation for 30–45 min.Epithelial cell adhesion molecule sorting procedures
Cells were sorted for epithelial cell adhesion molecule
(EpCAM) using magnetic beads as indicated by the
manufacturer (MiltenyiBiotec Inc., Germany). Briefly,
the EpCAM+ cells were magnetically labeled with
EpCAM MicroBeads (catalog #130-061-101; Miltenyi-
Biotec Inc.) and loaded onto a MACS LS Column (cata-
log #130-042-401; MiltenyiBiotec Inc.) that was placed
in the magnetic field of a MACS Separator. EpCAM+
cells were suspended in basal medium at a concentration
of 300,000 cells/ml, and used as the final cell suspension.
Sorted cells were characterized extensively by FACS ana-
lysis for EpCAM and many mesenchymal cell markers
(CD45, CD31, CD34, CD90, α-SMA).
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All media were sterile filtered (0.22-μm filter) and kept
in the dark at 4 °C before use. RPMI-1640, the basal
medium used for all of the cell cultures, and fetal bovine
serum (FBS) were obtained from GIBCO/Invitrogen
(Carlsbad, CA, USA). All reagents were obtained from
Sigma (St. Louis, MO, USA) unless otherwise specified.
Kubota’s Medium
Kubota’s Medium (KM) is a serum-free medium devel-
oped for survival and expansion of endodermal stem/
progenitors [29] and subsequently shown to be success-
ful with human HpSCs [30, 31], hBTSCs [24, 26, 28, 32],
human pancreatic stem/progenitor cells [28], and rodent
HpSCs [14]. Mature endodermal cells do not survive in
KM [33].The detailed protocol of its preparation was
first reported by Kubota and Reid [29]. Briefly, KM con-
sists of any basal medium (here being RPMI 1640) with
no copper, low calcium (0.3 mM), 10–9 M selenium,
4.5 mM nicotinamide, 0.1 nM zinc sulfate heptahydrate,
10–8 M hydrocortisone (or dexamethasone), 5 μg/ml
transferrin/Fe, 5 μg/ml insulin, 10 μg/ml high-density
lipoprotein, 0.1% human (or bovine) serum albumin
(HSA or BSA), and a mixture of purified free fatty acids
that are added bound to purified HSA. The medium is
now available commercially through PhoenixSongs Bio-
logicals (Branford, CT, USA).
Coating by hyaluronic acid
HA gel was made using HA powder (#S0780000; Sigma)
dissolved in normal saline with a rate of 0.1% W/V and
filtered by 0.22 μm. hBTSCs were counted by trypan
blue, suspended with coating medium, mixed softly, and
stored in an incubator for 10 min at 37 °C and 5.0 CO2.
After 5 min in coating medium, hBTSCs were mixed
softly.
Cell cultures and clonal expansion
EpCAM+ hBTSCs (approximately 3 × 105 cells), HA-
coated or uncoated, were seeded onto 3-cm-diameter
plastic culture dishes and kept overnight (~12 hours) in
KM with 10% FBS. Thereafter cell cultures were main-
tained in serum-free KM. For testing the clonal expan-
sion of hBTSCs, a single cell suspension was obtained,
and the cells were plated on culture plastic at a clonal
seeding density (500/cm2) [34]. For in-vitro experiments,
cells were cultured in serum-free KM (without passing).
Cell viability
Cell viability was determined by trypan blue exclusion
assay (#302 643-25G; Sigma). The cells stained blue were
dead; the viable cells did not stain. This dye was used at
1:1 v/v with the cell buffer. The cell count was carried
out using FAST-READ 102 (#BSV100; Biosigma). Cellsviability was calculated at four different time points: 1, 3,
7, and 14 days.
Colony counting
The hBTSC colonies began to appear after 1 day of plat-
ing and were easily identified by observing at 10× with a
light microscope. Any size colony was counted as one,
whether large ones at >3000 cells or small ones at <200
cells. Each well of the six well plates was evaluated using
10× magnification for colonies and counted during
2 weeks of culture. Microscopic fields were used as
normalization. Observations of colony number, size, and
morphology were noted.
Population doubling
The proliferation rate was analyzed on the same hBTSC
population, seeded in six multiwell plates at a density of
1 × 104 cell/cm2, and cultured for 7 days. The cell counts
were performed under two culture conditions: hBTSCs
coated with HA; and hBTSCs uncoated.
The medium was changed every 3 days, using serum-
free KM. The mean cell number was calculated on three
experimental samples for each condition, and cell dens-
ity was expressed as the mean of cells/cm2 ± standard
deviation (SD). Cells were detached from supports and
were counted by trypan blue assay; for these experi-
ments we used only viable cells.
The population doubling time (PDT) was calculated
in the phase exponential growth by the following for-
mula [35]:
PDT¼log10xΔT=log10 N7dð Þ‐log10 N1dð Þ
where N7d is the cell number at day 7 and N1d is the cell
number at day 1.
To determine the population doubling (PD) rate, the
following formula was applied [35]:
PD¼log10 Nð Þ  log10 Nsð Þ=log10 2ð Þ
where N is the harvested cell number and Ns is the ini-
tial plated cell number.
Quantitative reverse-transcription polymerase chain
reaction analysis
Total RNA was extracted by the procedures of
Chomczynski and Sacchi [36]. The expression of the
genes was conducted by reverse-transcription and
PCR amplification performed in a closed tube (One-
Step RT-PCR; Qiagen, Hamburg, Germany) on total
RNA samples extracted from cells and tissues. These
genes were coamplified with the GAPDH housekeeping
gene as a reference. The mRNA expression was measured
by the quantification of amplicons with on-chip capillary
microelectrophoresis performed with the Experion System
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calculated by the ratio of the concentrations of the gene of
interest and the reference gene GAPDH “in vitro” and β-
actin “in vivo” (reported by the instrument in nmol/L)
(Additional file 1: Table S1).Immunofluorescence on cell cultures
For immunofluorescence (IF) on cell cultures, slide cham-
bers were fixed in acetone for 10 min at room
temperature and then rinsed with PBS-Tween 20. Non-
specific protein binding was blocked by 5% normal goat
serum. Fixed cells were incubated with primary antibodies
against HA (# BVN-3996 F-100; Vinci Biochem) and
CD44 (# 3570; Cell Signaling Technology). Cells were then
washed and incubated for 1 hour with labeled isotype-
specific secondary antibodies (anti-mouse AlexaFluor-488,
anti-rabbit AlexaFluor-594; Invitrogen, LifeTechnologies
Ltd, Paisley, UK) and counterstained with 4,6′-diamidino-
2-phenylindole (DAPI) for visualization of cell nuclei. For
all immunoreactions, negative controls were also included
and consisted of replacing the primary antibody with pre-
immune serum. Cultures were examined in a coded fash-
ion by Leica Microsystems DM 4500 B Light and
Fluorescence Microscopy (Weltzlar, Germany) equipped
with a JenoptikProg Res C10 Plus Videocam (Jena,
Germany). IF was also analyzed by confocal microscopy
(Leica TCS-SP2) [25].Cell transplantation in severely combined
immunodeficient mice
All animal experiments were carried out in accordance
with the EU Directive 2010/63/EU for animal experi-
ments and with Sapienza institutional guidelines. The
severely combined immunodeficient (SCID) mice (T/
SOPF NOD.CB17 PRKDC/J) were male, 4-week-old
animals and were used as the hosts for transplantation
of human cells. Animals were sedated with an
anesthetic drug (2, 2, 2-tribromoethanol). Thereafter,
2 × 106 hBTSCs coated with HA or uncoated (control
cells) were suspended in 100 μl saline and injected into
the liver via the spleen. Sham controls were infused
only with 100 μl saline or with HA buffer 0.1% w/v.
Then, 30 days after cell transplantation, mice were
sacrificed and the livers removed for further analyses.
Liver samples were placed in Trizol reagent for gene
analyses or in 4% formalin for pathologic and immu-
nohistochemistry (IHC) analyses. Blood samples were
collected from the heart, centrifuged, and serum sam-
ples stored at –20 °C for quantification of human albu-
min by enzyme-linked immunosorbent assay (ELISA)
(Albumin Human ELISA Kit, cat. N. ab108788;
Abcam, Cambridge, UK).Light microscopy and immunohistochemistry
Specimens were fixed in 10% buffered formalin for 2–4
hours, embedded in low-temperature-fusion paraffin
(55–57 °C), and 3–4 μm sections were stained with
hematoxylin–eosin and Sirius red/Fast green, according
to standard protocols. For IHC, endogenous peroxidase
activity was blocked by 30-min incubation in methanolic
hydrogen peroxide (2.5%). Antigens were retrieved, as
indicated by the vendor, by applying Proteinase K (code
S3020; Dako, Glostrup, Denmark) for 10 min at room
temperature. Sections were then incubated overnight at
4 °C with primary antibodies (Additional file 2: Table S2).
Samples were rinsed twice with PBS for 5 min, incubated
for 20 min at room temperature with secondary biotinyl-
ated antibody (LSAB+ System-HRP, code K0690; Dako)
and then with Streptavidin-HRP (LSAB+ System-HRP,
code K0690; Dako). Diaminobenzidine (Dako) was used as
a substrate, and sections were counterstained with
hematoxylin or with Periodic Acid–Schiff (PAS). For all
immunoreactions, negative controls were included by re-
placing the primary antibody with preimmune serum. Sec-
tions were examined in a coded fashion by Leica
Microsystems DM 4500 B Light and Fluorescence Mi-
croscopy (Weltzlar, Germany) equipped with a Jenop-
tikProg Res C10 Plus Videocam (Jena, Germany).
Observations were processed with an Image Analysis
System (IAS; Delta Sistemi, Rome, Italy) and were in-
dependently performed by two pathologists in a blind
fashion. A list of positive and negative controls is
presented in Additional file 3: Table S3.
For IF, nonspecific protein binding was blocked with
5% normal goat serum. Sections were incubated with
primary antibodies, and subsequently incubated with la-
beled isotype-specific secondary antibodies (anti-mouse
AlexaFluor-488 and anti-rabbit Alexafluor-594; Invitro-
gen Ltd) for 1 hour; nuclei were visualized with DAPI
[25]. To perform double immunostaining with two
mouse primary antibodies, we followed a three-step
protocol: sections were incubated with the first primary
antibody, an anti-mouse (or anti-rabbit) secondary fluor-
escent antibody (alexafluor-488) was applied, and the
second primary antibody was prelabeled with a fluoro-
phore using the APEX-594 labeling kit (Invitrogen) and
applied to the section. All antibodies were diluted (1:50)
and incubated for 1 hour. Slides were counterstained
with DAPI. For all immunoreactions, adequate negative
controls were also preformed [25].
All counts were performed in six nonoverlapping
fields (magnification 20×) for each slide; at least three
different slides were taken from each specimen. For
IHC/IF staining, the number of positive cells was
counted in a random, blinded fashion in six nonover-
lapping fields (magnification 20×) for each slide/cul-
ture, and the data are expressed as % positive cells. The
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tiation was assessed by IHC for anti-human antibodies
(anti-human mitochondria) which do not react with
mouse antigens, as described elsewhere [25].
Flow cytometry analysis
Isolated cells were labeled with fluorescent primary anti-
bodies or adequate isotype controls. Cells were resuspended
at approximately 2 × 105 cells/ml in PBS. Primary anti-
bodies included EpCAM (EpCAM-FITC, catalog #130-
080-301; MiltenyiBiotec Inc.), and many mesenchymal cell
markers (CD45, CD31, CD34, CD90, α-SMA) (detailed in-
formation presented in Additional file 2: Table S2). Cells
were analyzed by a BD FACScanto™ Flow Cytometer
(Becton, Dickinson and Company, NJ, USA). Ten thou-
sand events were acquired and analyzed by BD FACS-
Diva™ software (Becton, Dickinson and Company).
Statistical analysis
Data were expressed as mean ± SD. Statistical analyses
were performed by SPSS statistical software (SPSS Inc.,
Chicago IL, USA). Differences between groups for non-
normal distribution parameters were tested by Mann–
Whitney U tests. Statistical significance was set to p < 0.05.
Results
HA coating
Immediately after the isolation, hBTSCs were incubated
with 0.1% HA (# S0780000; Sigma) in KM (0.1% weight/
volume) and gently mixed for 10 min. The cells were
then cultured in serum-free KM.
After the coating procedure, cells were washed twice
with KM and observed by optical microscope. The HA
coating was evaluated by IF using an anti-HA antibody
(code PAA182Ge01; Cloud-Cclone Corp.) (Fig. 1a). The
expression of the HA receptor, CD44, was verified in
hBTSCs, coated and uncoated, as assayed by IF using
human CD44 specific antibody (mouse anti-CD44,
N#3570; Cell Signalling, Danvers, MA, USA) (Fig. 1a).
As shown in Fig. 1a, HA—marked by the specific antibo-
dy—uniformly covered hBTSCs, which resulted in cells
constantly positive for CD44. The procedure of cell coat-
ing resulted in the formation of cell clusters (2–5 cells)
with a diameter ranging from 12 to 19 μm. The forma-
tion of cell clusters (>2 cells) was significantly higher in
HA-coated versus uncoated hBTSCs (p < 0.05; N = 5).
Colony formation is a well-established parameter of
cell viability and attachment. Isolated HA-coated and
uncoated hBTSCs were plated onto culture plastics and
in KM at a density of 10,000 cells/ml, and after 3 days
in culture the colonies were counted (Fig. 1b, c). A sig-
nificantly higher number of cell colonies was present in
HA-coated as compared with uncoated hBTSCs(uncoated hBTSCs: 6.93 ± 1.39; HA-coated hBTSCs:
15.07 ± 2.69; p < 0.001; N = 3) (Fig. 1b, c).Effects of HA coating on hBTSC viability, proliferation,
and gene expression in vitro
Viability of HA-coated and uncoated control cells was
assessed (trypan blue exclusion) at different time points
(i.e., after their initial isolation or after 1, 3, 7, or 14 days
in culture). After their isolation and at days 1 and 3, via-
bility was similar between HA-coated and uncoated
hBTSC cultures (isolation: uncoated 90.12 ± 6.83%,
HA-coated 94.03 ± 2.32; day 1: uncoated 85.12 ± 6.83%,
HA-coated 93.03 ± 2.32; day 3: uncoated 95.27 ± 2.47%,
HA-coated 82.01 ± 7.92%; N = 3) (Fig. 2). By days 7 and
14, HA-coated hBTSCs cells showed an increased via-
bility with respect to control uncoated cells (day 7: un-
coated hBTSCs 70.06 ± 2.40%, HA-coated hBTSCs
79.24 ± 1.83%; p < 0.05; day 14: uncoated hBTSCs 74.73 ±
4.88%, HA-coated hBTSCs 87.83 ± 2.30; p < 0.05; N = 3,
Fig. 2).
The proliferation rate, evaluated by the PD method,
was markedly higher for HA-coated hBTSC cultures
than for the uncoated controls at all of the different
times of observation (day 1: 0.74 ± 0.06 vs 0.13 ± 0.11;
p < 0.05; N = 3; day 3: 2.03 ± 0.12 vs 0.77 ± 0.41; p < 0.05;
N = 3; day 7: 1.10 ± 0.09 vs 0.63 ± 0.03; p < 0.01; N = 3; day
14: 1.95 ± 0.03 vs 0.94 ± 0.22; p < 0.05; N = 3; Fig. 3). The
gene expression of different adhesion molecules was ana-
lyzed by quantitative reverse-transcription polymerase
chain reaction (RT-qPCR) in primary cultures of hBTSCs
under KM conditions, which were extensively character-
ized by FACS analysis for EpCAM and many mesenchy-
mal cell markers (CD45, CD31, CD34, CD90, α-SMA)
(data not shown).
HA-coated cells, as compared with uncoated cells, had
enhanced gene expression of integrin subunit beta 1
(ITGβ1) (day 3: 1.71 × 100 ± 2.14 × 10–1 vs 6.65 × 10–2 ±
1.02 × 10–2; N = 5; p < 0.01; day 7: 3.69 × 10–1 ± 3.24 × 10–2
vs 1.78 × 10–1 ± 1.26 × 10–2; N = 5; p < 0.01; Fig. 4a) and in-
tegrin subunit beta 4 (ITGβ4) (day 1: 7.93 × 10–6 ± 9.16 ×
10–7 vs 3.57 × 10–6 ± 3.57 × 10–7; N = 5; p < 0.05; day 3:
6.30 × 10–5 ± 1.48 × 10–5 vs 1.50 × 10–6 ± 4.32 × 10–7; N = 5;
p < 0.05; day 7: 3.43 × 10–5 ± 5.75 × 10–6 vs 1.43 × 10–6 ±
1.14 × 10–7; N = 5; p < 0.05; day 14: 7.63 × 10–5 ± 1.89 × 10–5
vs 2.33 × 10–6 ± 2.74 × 10–7; N = 5; p < 0.05; Fig. 4b). By con-
trast, HA-coated cells, when compared with uncoated cells,
showed a decrease gene expression of cadherin-1 (CDH1)
(day 1: 7.99 × 10–3 ± 8.33 × 10–4 vs 1.20 × 10–1 ± 1.53 × 10–2;
N = 5; p < 0.01; Fig. 4c) and CD44 (day 1: 2.36 × 10–2 ±
2.66 × 10–3 vs 9.24 × 10–2 ± 1.31 × 10–2; N = 5; p < 0.05; day
3: 4.71 × 10–2 ± 4.39 × 10–3 vs 6.25 × 10–2 ± 2.60 × 10–3;
N = 5; p < 0.01; day 7: 2.62 × 10–2 ± 2.17 × 10–3 vs 3.97 ×
10–2 ± 3.95 × 10–3; N = 5; p < 0.01; Fig. 4d).
Fig. 1 Successful hyaluronan (HA) coating. a HA coating. IF analysis of HA in uncoated (left panels) and HA-coated (right panels) human biliary tree
stem cells (hBTSCs) demonstrates expression of HA only in hBTSCs, which underwent a coating procedure (red dye; nuclei, blue dye) (40× magnifi-
cation). IF analysis of CD44 in uncoated (left panels) and HA-coated (right panels) hBTSCs demonstrates expression of CD44 in hBTSCs (CD44, green
dye; nuclei, blue dye) (40× magnification). This image is representative of the findings from n = 5 experiments. b Colony counting at day 3 in cul-
tures of HA-coated and uncoated hBTSCs. Optical microscope contrast phase appearance of cultures of HA-coated and uncoated hBTSCs. This
image is representative of the findings from n = 5 experiments (magnification 10×). c Histograms represent the number of colonies. Data
expressed as mean ± SD of n = 3 different experiments; *p < 0.00001
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intrasplenic transplantation in mice
To determine whether HA-coated hBTSCs engraft and
proliferate in mouse liver, cells were injected into the
liver via the spleen of SCID mice and, after 4 weeks, the
livers were analyzed by IHC utilizing an ultraspecific
anti-human mitochondria antibody. As shown in Fig. 5a,
uncoated and HA-coated hBTSCs engrafted into themurine liver parenchyma (N = 3). Specifically, the ex-
pression of human mitochondrial protein in liver paren-
chyma of the SCID mice indicated that 2.626 ± 1.53% and
11.015 ± 8.167% of parenchymal cell mass derived from
uncoated or HA-coated hBTSCs respectively (p < 0.05).
The quantitative analysis showed an increase (Fig. 5a)
in humanized host parenchymal cell mass when the
mice were transplanted with HA-coated hBTSCs as
Fig. 2 Cell viability of hyaluronan (HA)-coated and uncoated human
biliary tree stem cells (hBTSCs) at different times in cultures. After 7
and 14 days in culture, viability (trypan blue exclusion) was better in
HA-coated as compared with uncoated hBTSCs. Data expressed as
mean ± SD for three experiments; *p < 0.05
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demonstrating enhanced engraftment of HA-coated
hBTSCs. As expected, human cells were not present
within the liver of SCID mice infused either with nor-
mal saline (vehicle, Fig. 5a) or with HA buffer with nor-
mal saline (vehicle, Fig. 5a) or with HA buffer (Fig. 5a).
Interestingly, the study of mature hepatocyte markers
revealed that human mitochondria positive cells
showed signs of differentiation toward mature hepato-
cytes such as PAS positivity (glycogen storage), Hep-
Par1 positivity, Albumin positivity, and Mrp1 positivity
with a canalicular pattern expression.
At same time point, human albumin gene expression
in the liver was evaluated as a quantitative measure for
stem cell engraftment and as a sign of differentiation to-
ward mature human hepatocytes. Interestingly, before
transplantation into the host, both HA-coated and un-
coated freshly isolated hBTSCs showed minimal or null
mRNA albumin levels with respect to hBTSCs cultured
in high defined medium for hepatocyte differentiation
(HDM-H) or with respect to primary mature hepato-
cytes (Additional file 4: Figure S1). Human albumin ex-
pression was analyzed by RT-qPCR utilizing human and
mouse specific primer sequences. Data have been nor-
malized with β-actin as a housekeeping gene. In the liver
samples from mice transplanted with HA-coated
hBTSCs, human albumin gene expression was markedly
higher than in mice treated with uncoated hBTSCs
(1.00 ± 0.84 vs 0.000008 ± 7.29; N = 3; p < 0.05; Fig. 5b).
As a consequence, the human albumin/mouse albumin
ratio (ALB homo/ALB mouse) resulted in markedly
higher levels in mice treated with HA-coated than
uncoated hBTSCs (0.39 ± 0.31 vs 0.000036 ± 0.000014;
N = 3; p < 0.01). Circulating serum human albumin was
measured by ELISA in transplanted mice after 4 weeks
from transplantation. Mice treated with HA-coated
hBTSCs showed a concentration of serum human albu-
min that was approximately double that found in mice
transplanted with uncoated hBTSCs (117.62 ± 18.20 vs
64.94 ± 15 ng/dl; N = 3; p < 0.05; Fig. 5c). Human albu-
min was undetectable in sham operated control mice
by the ELISA assay we used (n = 3; Fig. 5c).
Evaluation of ectopic distribution and seeding of
transplanted cells
To evaluate the possibility of ectopic distribution and
seeding of transplanted cells, distant organs, the lung, and
the kidney were analyzed for the occurrence of human cell
Fig. 3 Population Doubling (PD) of uncoated versus hyaluronan
(HA)-coated human biliary tree stem cells (hBTSCs) at different times
in culture. PD was always higher in HA-coated cells as compared
with uncoated hBTSCs. Data expressed as mean ± SD for three
experiments; *p < 0.05, §p < 0.01
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variably normal with respect to histomorphological as-
pects (N = 3; Fig. 6). By IHC, few and scattered human
mitochondria positive cells (arrows) were identified; the
extent of ectopic cell distribution was similar in mice
transplanted with uncoated versus coated BTSCs (N = 3;
Fig. 6). Also the kidney appeared invariably normal with
respect to the histomorphological aspects (N = 3; Fig. 6)
and, by IHC, no human Hep-Par1+ cells were seen (Fig. 6).
However, the IHC using an antibody to human mitochon-
dria resulted in staining of renal tubules (not shown) in
transplanted mice (hBTSCs vs HA-coated hBTSCs) as
well as in sham transplanted (control) mice. We speculate
that this might be nonspecific staining (i.e., cross-
contamination in staining). Finally, no tumoral mass has
been observed in the abdomen, liver, spleen, kidney, lungs,
or derma at sacrifice.Discussion
Coating of hBTSCs with hyaluronans (HA) resulted in
significant improvement in engraftment of cells deliv-
ered by a vascular route to the liver. Many different
strategies are currently under investigation to improve
cell grafting, including the use of organic and inorganic
biomatrices mimicking the microenvironment offered by
the extracellular matrix [7, 37, 38]. HAs, major constitu-
ents of stem cell niches, are candidate coatings of stem
cells used for cell therapies because they facilitate viabil-
ity, proliferation, and engraftment in damaged livers.
The chemical and mechanical properties of HA are con-
ducive to essential requirements for stem cells. In
addition, because the liver is a primary site for HA clear-
ance, HA coating represents an advantageous strategy
for the selective targeting of the transplanted cells to the
liver. In our work, we tested the coating of hBTSCs with
HA for its influence on engraftment into livers.
This molecule is already approved for Good Manufactory
Practice (GMP) use and has been tested in clinical trials
evaluating its effect on dental implant placement [39, 40],
on treatment of arthritis after injections into joints [39],
and for various types of cosmetic surgery [40].
A simple and rapid coating protocol was achieved and
consisted of incubating cells in a 0.1% HA (weight/vol-
ume) solution for 10 min at room temperature. The IF
analysis showed that HA was uniformly distributed
around the whole cell surface, representing a homoge-
neous coating that was stable throughout the 2-week
Fig. 4 Expression of adhesion molecule genes in culture of
hyaluronan (HA)-coated and uncoated human biliary tree stem cells
(hBTSCs). a Gene expression of integrin subunit beta 1 (ITGβ1) in
HA-coated hBTSCs (dark gray columns) was higher (days 3 and 7)
than uncoated hBTSCs (light gray columns). Data expressed as mean
± SD of n = 5 experiments; §p < 0.01. b Gene expression of integrin
subunit beta 4 (ITGβ4) in HA-coated hBTSCs was higher (days 1, 3, 7,
and 14) than in uncoated hBTSCs. Data expressed as mean ± SD of
n = 5 experiments; *p < 0.05. c Gene expression of E-cadherin (CDH1)
in uncoated hBTSCs was higher (day 1) than in HA-coated hBTSCs.
Data expressed as mean ± SD of n = 5 experiments; §p < 0.01. d
Gene expression of CD44 in uncoated hBTSCs was higher (days 1, 3,
and 7) than in HA-coated hBTSCs. Data expressed as mean ± SD of
n = 5 experiments; *p < 0.05, §p < 0.01
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findings but with polyethylene glycol (PEG).
A crucial issue in cell therapies is the size of trans-
planted cells. If the cells are large or if they form large
aggregates, the transplantation of them via a vascular
route can result in an embolus that can be life threaten-
ing. If the cells are small, their engraftment efficiency
can be very low, and the cells will have a greater propen-
sity to distribute to ectopic sites. Both possibilities are of
importance for stem cell therapy considerations. Cells
used for cell therapy of liver diseases have been infused
into the liver via the spleen in animal models or into the
portal vein or hepatic artery in humans. The sizes in
terms of the cell diameters have ranged from ~8–10 μm
for stem cells (ESCs, HpSCs, BTSCs), to ~12–15 μm for
hepatoblasts and committed progenitors, to ~17–18 μm
for diploid hepatocytes, found in abundance in neonatal
livers, to ~25–30 μm for mature hepatocytes that are
dominant in adult livers [2, 3, 6]. Engraftment efficien-
cies of less than 5% were reported for stem cells when
delivered by vascular routes into the livers of primates
[6] or in the livers of humans when injected into the
portal vein [8]. Engraftment efficiencies were increased
to 20–25% if delivered via the hepatic artery [8].
In these studies with HA coatings, the danger of
thrombi generation has been minimized, because the
coating process did not result in large cell clusters. The
dimensions of HA-coated hBTSC aggregates (maximum
of 3 cells) were within the range of previous studies with
uncoated cells (<30 μm), and therefore their administra-
tion is hypothesized to be safe.
HA coatings resulted in significant improvements in
hBTSC biological properties essential for transplantation
and engraftment. Cell viability, colony formation cap-
acity, and PD of HA-coated hBTSCs were better than
uncoated cells, as verified in long-term cultures corrob-
orating prior reports of the effects of HA on both nor-
mal cells [7, 11, 17, 28], in protecting cells under
cryopreservation conditions [16], and in support of
Fig. 5 In-vivo engraftment of human biliary tree stem cells (hBTSCs) after intrasplenic transplantation in mice. a Four weeks after hBTSC injection
into the spleen, the livers were analyzed by immunohistochemistry (IHC) utilizing anti-human (h) mitochondria. Expression of human mitochondria
antigen in liver parenchyma of SCID mice indicated that a higher proportion of liver murine parenchyma was repopulated by human cells in mice
transplanted with HA-coated hBTSCs in comparison with mice injected with uncoated cells. No positive cells have been found in control groups. b
Signs of differentiation toward mature hepatocyte were revealed in anti-mitochondria positive cells within the livers of mice injected with HA-coated
hBTSCs. In particular, human cells showed glycogen storage (PAS positivity, arrows), Hep-Par-1 expression (arrow), and the expression of multidrug
resistance-associated protein 2 (Mrp-2) in a canalicular pattern. Original magnification (OM) = 40×. c Anti-human mitochondria positive cells within
the livers of mice injected with HA-coated hBTSCs showed positivity for anti-human albumin (arrows). OM = 40×. d RT-qPCR expression of hu-
man albumin in the livers of mice transplanted with HA-coated versus uncoated hBTSCs. After 30 days, human albumin gene expression in
the livers of mice transplanted with HA-coated cells was markedly higher than in mice transplanted with uncoated hBTSCs. e Human serum al-
bumin in mice transplanted with HA-coated and uncoated hBTSCs. Human albumin concentration measured in the serum of mice trans-
planted with HA-coated hBTSCs was double that of mice transplanted with uncoated hBTSCs. HA hyaluronan, PAS Periodic Acid–Schiff
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vival and proliferation in vivo [15].
A facet of the ability of the HA coating to facilitate
these biologic properties is its ability to maintain critical
cell adhesion molecules needed for cell attachment and
cell–cell interactions and to prevent them from internal-
ization following cell suspension preparations or with
transplantation [7]. We analyzed ITGβ1 (CD29) and
ITGβ4 (CD104) integrins that bind, respectively, colla-
gen type III and laminin, CD44, a primary receptor for
HA, and, finally, CDH1 (also known as E-cadherin)
which allows the formation of cell–cell bonds. A signifi-
cant enhanced expression of the two integrins, ITGβ1and ITGβ4, was observed in HA-coated cells and is con-
sistent with the improved in-vitro properties and en-
hanced engraftment in vivo.
In light of the promising in-vitro findings, we next
moved on to in-vivo experiments aimed at evaluating
whether HA coating could improve the liver engraftment
of hBTSCs. The intrasplenic infusion route was chosen,
because it is largely utilized in preclinical studies with dif-
ferent cell types such as hBTSCs. The intrasplenic infusion
delivers the cells via the portal vein, a route that routinely
yields ~3% engraftment. Our data indicated that HA coat-
ing enhanced by 4-fold the engraftment efficiency without
detectable spreading of the cells to the kidney and with no
Fig. 6 Histomorphological analysis of distant organs to assess ectopic cell distribution. The lung and the kidney were evaluated by histology and
immunohistochemistry (IHC) to test the occurrence of ectopic distribution of human cell emboli. With respect to the lung (a), hematoxylin and eosin (H&E)
staining revealed normal histomorphological aspects. Few and scattered human mitochondria positive cells (arrows) were observed, without differences in
their numbers between animals transplanted with uncoated versus HA-coated hBTSCs (a). Also the kidney appeared invariably normal (b) with respect
to the histomorphological aspects; no human Hep-Par1+ cells were identified by IHC. HA hyaluronan, hBTSC human biliary tree stem cells
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coated cells. In addition, the appearance of signs of differ-
entiation toward mature cells was revealed in engrafted
cells. Indeed, using RT-qPCR we demonstrated that, after
30 days, gene expression of human albumin in the mouse
liver was markedly enhanced and, consistently, human
serum albumin was doubled in mice transplanted with
HA-coated vs uncoated hBTSCs. Our method of humanalbumin detection is highly sensitive, because our primers
accurately discriminate between human and mouse albu-
min, minimizing the possibility of interference. Indeed, we
designed primers by considering a specific adenine in the
albumin gene sequence that allows a perfect discrimination
between the human and murine albumin genes; this aden-
ine avoids the annealing of the primer with the cDNA of
murine albumin. Notably, the gene expression and the
Nevi et al. Stem Cell Research & Therapy  (2017) 8:68 Page 12 of 14protein concentration of the albumin in the serum of mice
are not directly linked. Different biologic processes involved
in the production secretion, metabolism, and excretion of
human albumin in the serum of the treated mice could ac-
count for this apparent discrepancy. The results concerning
albumin secretion are in touch with the IHC observations
which showed appearance of signs of differentiation toward
mature cells rather than complete differentiation.
In substance, our results indicate that HA coating
plays a key role in cell adhesion also in vivo. HA should
create a favorable microenvironment allowing a greater
number of hBTSCs to engraft within the liver paren-
chyma, survive, proliferate, and enhance human albumin
secretion. When, in previous studies, fibrin was tested,
instead of the HA, the same phenomenon was observed
[6]. In favor of our proposal is the fact that HA is dis-
posable in GMP grade for clinical use and, primarily,
that it is selectively and actively cleared by the liver, an
enormous advantage for cell therapies targeting the liver
[23]. Therefore, performing the infusion of HA-coated
hBTSCs in the portal vein—and even more so via the
hepatic artery, if that proves feasible—could permit a
greater number of cells to remain confined to the liver
without increased extra-hepatic distribution. HA coating
could play additional beneficial effects on cell therapy
because HA can stimulate the expression of adhesion mol-
ecules, thus favoring the proliferation and engraftment of
hBTSCs. Previous studies highlighted varied HA trophic
effects in different cell systems [12, 13, 20, 21, 38, 42]. HA
plays a key role in stabilizing and organizing the ECM by
adjusting the adhesion and cell motility, mediating prolifer-
ation and differentiation as exemplified in the following
examples. The authors demonstrated paracrine interactions
between the implanted cells, the host ECM, and endothe-
lial cells, and a proangiogenic effect of degradation of
exogenous HA [12, 13, 20, 21, 38, 42].
A current limit of this study is the lack of a proof of per-
formance of HA-coated hBTSCs in experimental models
of liver diseases. However, the results obtained and previ-
ous observations by Carpino et al. [25] on the effects of
freshly isolated hBTSCs infused in mice subjected to liver
fibrosis/cirrhosis induced by carbon tetrachloride, demon-
strating an improvement of serum liver biochemistry,
guarantee further experiments where hBTSCs will be sub-
jected to HA coating before cell transplantation.
Ectopic cell distribution has been shown to occur fol-
lowing transplants of stem cells into the liver, whether
by vascular route or by direct injection, a finding of un-
known importance clinically. Ectopic loci of transplanted
uncoated cells occurred in all tissues in prior studies.
Most studies assumed that the cells did not survive.
However, more recent investigations have indicated that
the ectopic sites are in most (if not all) tissues where the
cells survived for months and could be identified usingpositron emission tomography [7]. In this study, we have
evaluated both the lung and the kidney to test the occur-
rence of ectopic human cell emboli. Both the lungs and the
kidneys appeared invariably normal with respect to histo-
morphological aspects. By IHC, ectopic distribution oc-
curred only in the lungs and at levels comparable with that
found for uncoated cells. This distribution did not occur in
the kidneys, a second site known for HA clearance.
An especially advantageous aspect of using HAs to fa-
cilitate engraftment is that they are anti-inflammatory and
entirely biocompatible. In prior studies with use of HAs
for diverse forms of transplantations, they minimize fi-
brotic reactions and foster vascularization that facilitates
engraftment [4]. Finally, no tumoral mass has been ob-
served into the abdomen, liver, spleen, kidney, lungs, or
derma at sacrifice, confirming results of prior reports in
which the oncogenic potential of transplanted hBTSCs
has been evaluated after months and has resulted in a
complete absence of tumor formation [24, 25].
Conclusion
We are proposing a simple, rapid, effective, and safe
method to improve liver engraftment of transplanted
cells for use in the cell therapy of liver diseases. HA-
coated hBTSCs can be used immediately in clinical stud-
ies because HA is available in GMP conditions.
In summary, coating of hBTSCs with HAs resulted in a
4-fold increase (from ~3% to 11%) in engraftment even
when delivered by the portal vein. It will be interesting to
see whether HA coating increases the engraftment by an
equivalent fold increase if injected into the hepatic artery,
where prior findings of uncoated stem cells have indicated
an engraftment of 20–25%. Clearly, this simple procedure
of coating cells with HAs enables optimized engraftment
of cells into the liver when delivered by a vascular route.Additional files
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